Recursion Pharmaceuticals Inc (NASDAQ:RXRX) price on current trading day, rose 17.13% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $4.65.
A look at the stock’s price movement, the close in the last trading session was $3.97, moving within a range at $3.79 and $4.9683. The beta value (5-Year monthly) was 0.995. Turning to its 52-week performance, $12.36 and $3.80 were the 52-week high and 52-week low respectively. Overall, RXRX moved -23.27% over the past month.
Recursion Pharmaceuticals Inc’s market cap currently stands at around $1.87 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-27.
Analysts have a consensus estimate of 18.12M for the company’s revenue for the quarter, with a low and high estimate of 6M and 34.3M respectively. The average forecast suggests up to a 31.34% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 95.84M, representing a 62.88% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RXRX is a 100% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 2 recommend RXRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RXRX’s current price about -18.47% and -33.38% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 36.48, while 7-day volatility ratio is 18.03% and 9.19% in the 30-day chart. Further, Recursion Pharmaceuticals Inc (RXRX) has a beta value of 1.12, and an average true range (ATR) of 0.62. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -29.03% off current price level while to achieve the yearly target high, price needs to move -29.03%. Nonetheless, investors will most likely welcome a -29.03% jump to $6 which is the analysts’ median price.
If we refocus on Recursion Pharmaceuticals Inc (NASDAQ:RXRX), historical trading data shows that trading volumes averaged 21.44 over the past 10 days and 23.63 million over the past 3 months. The company’s latest data on shares outstanding shows there are 389.55 million shares.
The 23.91% of Recursion Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 60.17% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 86.42 million on 2025-03-14, giving us a short ratio of 2.75. The data shows that as of 2025-03-14 short interest in Recursion Pharmaceuticals Inc (RXRX) stood at 2338.0000000000005 of shares outstanding, with shares short rising to 75.45 million registered in 2025-02-14. Current price change has pushed the stock -31.21% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RXRX stock continues to rise going into the next quarter.
